Tazarotene

A to Z Drug Facts

Tazarotene

 Action
 Indications
 Contraindications
 Route/Dosage
 Interactions
 Lab Test Interferences
 Adverse Reactions
 Precautions
Patient Care Considerations
 Administration/Storage
 Assessment/Interventions
 Patient/Family Education


(tazz-AHR-oh-teen)
Avage
Tazorac
Cream: 0.05%
Cream: 0.1%
Gel: 0.05%
Gel: 0.1%
Class: Retinoid

 Action Undefined; however, inhibits cornified envelope formation, which is an element of psoriatic scales.

 Indications Treatment of acne (Tazorac cream and gel), psoriasis (Tazorac gel); as an adjunctive agent in mitigation of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs (Avage).

 Contraindications Pregnancy; hypersensitivity to any component of the product.

 Route/Dosage

Acne

Adults and Children (12 yr and older): Topical After gently cleansing and drying the face, apply a thin film (2 mg/cm2) once daily in the evening where acne lesions appear.

Psoriasis

Adults (18 yr and older): Topical Apply once a day in the evening to psoriatic lesions, using enough (2 mg/cm2) to cover only the lesion with a thin film.

Wrinkling, Hyper- and Hypopigmentation, Lentigines

Adults (18 yr and older): Topical Apply pea-sized amount once daily at bedtime to lightly cover the entire face including the eyelids if desired.

 Interactions None well documented.

 Lab Test Interferences None well documented.

 Adverse Reactions

DERMATOLOGIC: Skin pain (Tazorac); skin inflammation, worsening of psoriasis, rash (Tazorac for psoriasis); desquamation; stinging; dry skin; erythema; pruritus; skin irritation; burning sensation; fissuring localized edema, skin discoloration (Tazorac gel for acne); irritant contact dermatitis; fissuring; bleeding (Tazorac gel for psoriasis); contact dermatitis; dermatitis; eczema; peripheral edema (Tazorac cream for psoriasis); irritant contact dermatitis; acne; rash; cheilitis (Avage). METABOLIC: Hypertriglyceridemia (Tazorac cream for psoriasis)

 Precautions

Pregnancy: Category X. Lactation: Undetermined. Children: Safety and efficacy not established in patients with psoriasis under 18 yr or under 12 yr with acne (cream). Safety and efficacy not established in children under 12 yr (gel). Safety and efficacy not established in patients under 17 yr with facial fine wrinkling, facial mottled hypo- and hyperpigmentation and benign facial lentigines (Avage). Photosensitivity: Use with caution if patient is known to be taking a photosensitizing drug because of increased risk of photosensitivity. Special risk patients: Avoid use on eczematous skin and avoid concurrent use of medications and cosmetics that have a strong drying effect; assess facial pigmented lesions before use.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
 Marked redness, peeling, discomfort

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts